Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel. [PDF]
Future OncolArdizzoni A +5 more
europepmc +1 more source
Response to anaplastic lymphoma kinase inhibitor in gastric cancer harboring <i>DCTN1-ALK</i> fusion: a case report and review. [PDF]
Front ImmunolWang H, You L, Pan H, Qiu X, Sheng J.
europepmc +1 more source
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an <i>ALK+</i> NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib. [PDF]
Lung Cancer (Auckl)Ou SI, Park CJ, Arter ZL, Nagasaka M.
europepmc +1 more source
Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes. [PDF]
JTO Clin Res RepSinghal S +10 more
europepmc +1 more source
Case Report: Locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib. [PDF]
Front PharmacolXue Y, Li W, Huang K, Zhou Q, Wu Q.
europepmc +1 more source
Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer. [PDF]
Transl Lung Cancer ResMorise M, Tanaka I, Ishii M.
europepmc +1 more source
Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database. [PDF]
Sci ProgZhao W, Jin X, Li Y, Peng H, Jiang J.
europepmc +1 more source
The Evolving Interplay Between Targeted Therapy and Surgery for Resectable Lung Cancer. [PDF]
Cancers (Basel)Yin V, Antonoff MB.
europepmc +1 more source
ALK-positive adult histiocytosis with a TFG-ALKfusion gene. [PDF]
OncologistLee JY +9 more
europepmc +1 more source